CanSinoBIO’s inhaled COVID vaccine candidate triggers immune response-early trial
An inhaled version of CanSino Biologics' (CanSinoBIO) COVID-19 vaccine triggered immune responses without serious side effects, an early-stage clinical trial showed. The two-dose candidate requires lower dosages than the…